Patents by Inventor Helen M. Blau
Helen M. Blau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11969433Abstract: Provided herein are compositions, methods, and kits for proliferating muscle cells by exposing the muscle cells to a prostaglandin E2 (PGE2) compound or compound that activates PGE2 signaling. Also provided are methods for regenerating muscle in a subject suffering from muscular atrophy, dystrophy, and/or injury by administering a PGE2 compound alone or in combination with isolated muscle cells. The PGE2 compound in combination with the isolated muscle cells can be administered prophylactically to prevent a muscle disease or condition.Type: GrantFiled: August 22, 2019Date of Patent: April 30, 2024Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Helen M. Blau, Andrew Tri Van Ho, Adelaida R. Palla
-
Publication number: 20240115583Abstract: Provided herein are compositions for preventing or treating muscle conditions such as muscle damage, injury, or atrophy. In some embodiments, the compositions comprise a prostaglandin E2 (PGE2) compound and a myotoxin. In some embodiments, the muscle damage, injury, or atrophy is the result of a nerve injury, a surgical procedure, or a traumatic injury. Methods of promoting muscle regeneration and methods of increasing muscle mass are also provided herein.Type: ApplicationFiled: May 15, 2023Publication date: April 11, 2024Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Helen M. Blau, Adelaida R. Palla, Andrew Tri Van Ho
-
Publication number: 20240100027Abstract: The present disclosure provides methods of improving the structure and/or function of a joint tissue of a subject by administering to the subject an amount of a 15-PGDH inhibitor effective to inhibit 15-PGDH activity and/or reduce 15-PGDH levels in the subject. The methods described herein are useful for treating joint dysfunction and/or degeneration associated with aging, injury, disease, disorder, and/or condition.Type: ApplicationFiled: December 9, 2021Publication date: March 28, 2024Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Helen M. BLAU, Nidhi BHUTANI, Mamta SINGLA, Adelaida Rosa PALLA
-
Patent number: 11872243Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.Type: GrantFiled: January 6, 2020Date of Patent: January 16, 2024Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: John Ramunas, Eduard Yakubov, Helen M. Blau, John Cooke
-
Publication number: 20240000758Abstract: The present disclosure provides methods of increasing mitochondrial biogenesis, function, or both in a tissue of a subject by administering to the subject an amount of a 15-PGDH inhibitor effective to inhibit 15-PGDH activity and/or reduce 15-PGDH levels in the subject. The methods described herein are useful for treating diseases, disorders, or conditions associated with dysfunctional mitochondria and/or increased oxidative stress including mitochondrial diseases.Type: ApplicationFiled: October 22, 2021Publication date: January 4, 2024Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Helen M. BLAU, Adelaida Rosa PALLA, Meenakshi RAVICHANDRAN
-
Patent number: 11738031Abstract: Provided herein are compositions for preventing or treating muscle conditions such as muscle damage, injury, or atrophy. In some embodiments, the compositions comprise a prostaglandin E2 (PGE2) compound and a myotoxin. In some embodiments, the muscle damage, injury, or atrophy is the result of a nerve injury, a surgical procedure, or a traumatic injury. Methods of promoting muscle regeneration and methods of increasing muscle mass are also provided herein.Type: GrantFiled: August 11, 2021Date of Patent: August 29, 2023Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Helen M. Blau, Adelaida R. Palla, Andrew Tri Van Ho
-
Publication number: 20230220075Abstract: The present disclosure provides compositions and methods based on the inhibition of thrombospondin-1 as a therapeutic target in aging skeletal muscle to improve muscle mass, strength, function, maintenance, and regeneration.Type: ApplicationFiled: June 22, 2021Publication date: July 13, 2023Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Helen M. Blau, Ermelinda Porpiglia, David M. Burns
-
Publication number: 20230210829Abstract: The present disclosure provides compositions and methods based on the use of 15-PGDH as a therapeutic target in rejuvenation of aging non-skeletal muscle tissues and/or organs. The 15-PGDH inhibitor SW033291 administered intraperitoneally for 4 weeks resulted in restoration of follicular structure and re-establishment of the marginal zone in spleens of 25 month old mice. Treatment of 25 month old mice with SW033291 also reduced the levels of IL10, IL6, BTC, GM-CSF, IL 13 back to levels similar 0 to 4 month old mice.Type: ApplicationFiled: June 11, 2021Publication date: July 6, 2023Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Helen M. Blau, Adelaida Rosa Palla, Yu Xin Wang
-
Publication number: 20230088271Abstract: The present disclosure describes systems and methods for determining spatial accumulation of signaling molecules within tissue samples. Embodiments of the present disclosure are directed to integrating spatial and expression data for cells in a tissue. Embodiments further describe identifying cell linkages and rendering transcriptome profiles to spatial coordinates. Some embodiments further convolve diffusion information for various ligands and measure effective concentrations within cell areas. Using this information, embodiments are able to predict cell-cell signaling information.Type: ApplicationFiled: March 1, 2021Publication date: March 23, 2023Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Helen M. Blau, Yu Xin Wang, Colin A. Holbrook
-
Patent number: 11597976Abstract: Shortened telomeres are diagnostic of genetic predisposition to cardiomyopathies, e.g. those related to defects in structural proteins expressed in cardiomyocytes.Type: GrantFiled: February 22, 2017Date of Patent: March 7, 2023Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Helen M. Blau, Chia Yu Alex Chang
-
Publication number: 20220304992Abstract: The present disclosure provides compositions and methods based on the identification of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as a therapeutic target in aging, dystrophic muscle to improve muscle atrophy, increase muscle mass, function and strength. Further provided herein are compositions and methods for the rejuvenation of aged tissue. In particular, 15-PGDH inhibitors, such as SW033291, are used to elevate the levels of prostaglandin E2 (PGE2) in the muscle or tissue.Type: ApplicationFiled: June 11, 2020Publication date: September 29, 2022Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Helen M. Blau, Adelaida Rosa Palla, Andrew Tri Van Ho
-
Publication number: 20220265677Abstract: Provided herein are compositions for preventing or treating muscle conditions such as muscle damage, injury, or atrophy. In some embodiments, the compositions comprise a prostaglandin E2 (PGE2) compound and a myotoxin. In some embodiments, the muscle damage, injury, or atrophy is the result of a nerve injury, a surgical procedure, or a traumatic injury. Methods of promoting muscle regeneration and methods of increasing muscle mass are also provided herein.Type: ApplicationFiled: August 11, 2021Publication date: August 25, 2022Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Helen M. Blau, Adelaida R. Palla, Andrew Tri Van Ho
-
Patent number: 11007210Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.Type: GrantFiled: January 6, 2020Date of Patent: May 18, 2021Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: John Ramunas, Eduard Yakubov, Helen M. Blau, John Cooke
-
Publication number: 20200281959Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.Type: ApplicationFiled: January 6, 2020Publication date: September 10, 2020Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: John RAMUNAS, Eduard YAKUBOV, Helen M. BLAU, John COOKE
-
Publication number: 20200215095Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.Type: ApplicationFiled: January 6, 2020Publication date: July 9, 2020Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: John RAMUNAS, Eduard YAKUBOV, Helen M. BLAU, John COOKE
-
Publication number: 20200215094Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.Type: ApplicationFiled: January 6, 2020Publication date: July 9, 2020Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: John RAMUNAS, Eduard YAKUBOV, Helen M. BLAU, John COOKE
-
Publication number: 20200147103Abstract: Provided herein are compositions, methods, and kits for proliferating muscle cells by exposing the muscle cells to a prostaglandin E2 (PGE2) compound or compound that activates PGE2 signaling. Also provided are methods for regenerating muscle in a subject suffering from muscular atrophy, dystrophy, and/or injury by administering a PGE2 compound alone or in combination with isolated muscle cells. The PGE2 compound in combination with the isolated muscle cells can be administered prophylactically to prevent a muscle disease or condition.Type: ApplicationFiled: August 22, 2019Publication date: May 14, 2020Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Helen M. Blau, Andrew Tri Van Ho, Adelaida R. Palla
-
Patent number: 10525075Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.Type: GrantFiled: February 22, 2014Date of Patent: January 7, 2020Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: John Ramunas, Eduard Yakubov, Helen M. Blau, John Cooke
-
Patent number: 10449205Abstract: Provided herein are compositions, methods, and kits for proliferating muscle cells by exposing the muscle cells to a prostaglandin E2 (PGE2) compound or compound that activates PGE2 signaling. Also provided are methods for regenerating muscle in a subject suffering from muscular atrophy, dystrophy, and/or injury by administering a PGE2 compound alone or in combination with isolated muscle cells. The PGE2 compound in combination with the isolated muscle cells can be administered prophylactically to prevent a muscle disease or condition.Type: GrantFiled: February 7, 2018Date of Patent: October 22, 2019Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Helen M. Blau, Andrew Tri Van Ho, Adelaida R. Palla
-
Publication number: 20190167695Abstract: Provided herein are compositions for preventing or treating muscle conditions such as muscle damage, injury, or atrophy. In some embodiments, the compositions comprise a prostaglandin E2 (PGE2) compound and a myotoxin. In some embodiments, the muscle damage, injury, or atrophy is the result of a nerve injury, a surgical procedure, or a traumatic injury. Methods of promoting muscle regeneration and methods of increasing muscle mass are also provided herein.Type: ApplicationFiled: October 1, 2018Publication date: June 6, 2019Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Helen M. Blau, Adelaida R. Palla, Andrew Tri Van Ho